ABSTRACT-Binding affinities of serotonin (5-HT)-receptor antagonists and agonists at human recombinant a1-adrenoceptor subtypes (a 1a-, a1b-and a1d-subtypes) were examined and compared with the functional affinities obtained in rat caudal artery (a1A-subtype), dog carotid artery (a1B-subtype) and rat thoracic aorta (=1D-subtype). Most of the 5-HT-receptor antagonists and agonists tested showed relatively high affinity to three a 1-adrenoceptor subtypes. The highest affinity close to 1 nM was seen for in binding and functional studies. 5-Methylurapidil (5-HT1A agonist) and BMY7378 (5-HT1A agonist) showed, respectively, a 1a(a 1A)-or a1d(a1D)-subtype selectivity in both binding and functional affinities, but spiperone (5-HT2A antagonist) showed a1b-selectivity only in binding affinity. Functional affinity of ritanserin (5-HT2A antagonist) to the a1B-subtype was approximately 500-fold lower than that of affinity to the =1b-subtype. The present results show that many 5-HT-receptor antagonists and agonists have high affinity to a1-adrenoceptors, but suggest that there is deviation between their functional affinities and binding affinities for some drugs.
a1-Adrenoceptors comprise a heterogeneous family (1 -3) . Molecular biological studies have provided evidence for the existence of at least three genes encoding a1a-, a1b-and a1d-adrenoceptors (with lowercase letters) that correspond to the pharmacologically defined native a1A-, a1B-and a 1D-adrenoceptors (with uppercase letters) (4, 5) . Pharmacological studies have revealed several subtypeselective agents: for example, 5-methylurapidil, KMD-3213, RS-17053 and nigludipine for the a1a-subtype (6 -9); spiperone for the a1b-subtype (10); and BMY7378 for the a1d-subtype (11, 12) . Among them, 5-methylurapidil, spiperone and BMY7378 were originally categorized in serotonin (5-HT) receptor agonists and / or antagonists.
Many 5-HT receptor antagonists have been developed and some of them are now clinically used as anticoagulants, antihypertensive drugs and antipsychotic drugs (13, 14) . Such therapeutic diversity of 5-HT antagonists may be related to their wide spectrum for not only 5-HT receptor family but also for heterogeneous receptors such as dopamine receptors and a1-adrenoceptors (15, 16) .
The present study was undertaken to examine the possible selectivity for a1-adrenoceptor subtypes of 5-HT receptor agonists and antagonists including clinically active antipsychotic drugs. The selectivity was evaluated with two parameters: binding affinity to recombinant human a 1a-, a1b-and a1d-adrenoceptors expressed in Chinese hamster ovary (CHO) cells and functional affinity to native a1A-(rat caudal artery) (17), a 1B-(dog carotid artery) (18, 19) and a 1D-(rat thoracic aorta) (20) adrenoceptors. A good relationship was already reported for a 1-adrenoceptorselective drugs between the recombinant and native a1-adrenoceptors (7, 21) .
MATERIALS AND METHODS

Membrane preparation and radioligand binding experiments
cDNAs of human a 1a-, a1b-and a1d-adrenoceptors were constructed in pCR3 vector (Invitrogen, Groningen, Netherlands) and stably transfected into CHO cells as described previously (22) . cDNA of a1d-adrenoceptor was kindly provided by Dr. K.P. Minneman, Emory University (USA). The harvested CHO cells were suspended in ice-cold assay buffer (Tris-HCl 50 mM, EDTA 1 mM, pH 7.4), sonicated and centrifuged at 3,000´g for 10 min. The supernatant was then centrifuged at 75,000´g for 30 min, and the resulting pellet was resuspended in assay buffer and used for binding (23) .
Functional experiments
Male Wistar rats (250 -350 g) and Beagle dogs (10 -15 kg) were used for the experiment. The animals had free access to food and water at all times. Dogs were sacrificed under anesthesia with pentobarbital, and rats were decapitated. The dog carotid artery and rat thoracic aorta and caudal artery were isolated immediately thereafter.
The isolated arteries were cleaned of adherent connective tissue and cut helically, and the endothelium was removed by gentle rubbing with filter paper. The strip was then mounted vertically in an organ bath containing 20 ml of Krebs-Henseleit solution: 112.0 mM NaCl, 5.9 mM KCl, 2.0 mM CaCl2, 1.2 mM MgCl2, 1.2 mM NaH2PO4, 25.0 NaHCO3 and 11.5 mM glucose, gassed with 5% CO2 and O2 and maintained at 37°C. Resting tension applied was 0.5 g for rat caudal artery, 1 g for rat thoracic aorta and 2 g for dog carotid artery, and the responses were recorded isometrically through force-displacement transducers. All preparations were equilibrated for 90 min before the following experiments.
Concentration-response curves were obtained by adding the agonist (NS-49 for rat caudal artery or noradrenaline for other arteries) in a cumulative fashion (7). The curves were drawn at least five times for the same strip, and the third curve was used as the control. After the control experiment, strips were incubated with 5-HT antagonists or agonists for 30 min before, and during, the construction of the curves. All the experiments were performed in the presence of 0.3 mM desipiramine and 5 mM deoxycorticosterone acetate to block neural and extraneural uptake of noradrenaline and 1 mM propranolol to block b -adrenoceptor. In addition, 0.1 mM rauwolscine was added in the case of rat caudal artery to avoid a2-adrenoceptor-mediated responses (7).
Data analyses
Data were given as the means ± S.E.M. Saturation and competition binding data were fitted to a one-site model. Analysis of radioligand binding data was performed with Prism Ò , a nonlinear curve-fitting program (Graph Pad, San Diego, CA, USA). When the Hill slope in competition binding data deviated from unity, IC50 values were converted to K i values.
In functional studies, antagonist affinity estimates were obtained by construction of Schild regressions and were constrained to a slope of unity (if not statistically different) according to the equation: pKB = log(cr -1) -log[antagonist], where cr is the concentration ratio between EC50 values (concentration for half-maximal response) in the presence or absence of the antagonist. The pK B value was also determined for a single concentration of antagonist by the contraction method (24) .
Drugs
The drugs used and their sources were the following: (-)-noradrenaline bitartrate (NA), desipiramine hydrochloride and metoclopramide monohydrochloride from Sigma 
RESULTS
Binding affinity
In saturation experiments, [ 3 H]-prazosin labeled the recombinant human a1-adrenoceptors expressed in CHO cells with a high affinity (pKd = 0.124 nM and Bmax = 970 fmol/mg protein for the a1a-subtype; 0.118 nM and 835 fmol /mg protein for the a1b-subtype; 0.613 nM and 154 fmol /mg protein for the a1d-subtype, respectively). Most of the tested drugs monophasically inhibited this binding. Table 1 shows the binding affinities (pKi) for 5-HT antagonists and agonists at the three subtypes. In general, the antagonists showed high affinity to the three subtypes and the agonists such as 5-HT and 8-OH-DPAT showed lower affinity. The highest affinity was subnanomolar level, which was seen for NAN-190. Comparison among the subtypes revealed relative selectivity of 5-methylurapidil and NAN-190 for the a1a-subtype, spiperone for the a 1b-subtype and BMY7378 for the a1d-subtype.
Functional affinity
Concentration-response curves mediated through a1-adrenoceptors in rat caudal artery, dog carotid artery and rat thoracic aorta were inhibited by several 5-HT receptor antagonists or agonists (Table 2 ). Among the drugs tested, NAN-190 was the strongest antagonist; pA 2 being close to 9. 5-Methylurapidil and BMY7378 showed relatively high selectivity to a1a-and a1d-subtypes, respectively. Ritanserin was somewhat inactive towards the a1b-subtype, comparing with a1a-and a 1d-subtypes. 5-HT and 8-OH-DPAT produced a contraction.
DISCUSSION
The present study clearly showed that many 5-HT receptor antagonists and agonists have high affinity to a1-adrenoceptors. The drug showing the highest affinity among tested drugs was NAN-190; its subnanomolar affinity is equal to that of a representative a1-adrenoceptor antagonist, prazosin (pKi = 9 -10) (4, 25, 26) . Furthermore, the binding affinity of NAN-190 for a 1-adrenoceptor was not different from that (pKi = 9.2) reported for 5-HT receptors (27) , indicating that this drug is an antagonist of not only the 5-HT receptor but also the a1-adrenoceptor.
5-Methylurapidil and BMY7378 are respectively known as an a 1a-or a1d-selective antagonist (6, 12) , which was confirmed in the present binding and functional studies. High affinity of spiperone to a1b-adrenoceptors has been demonstrated in binding studies (10, 28) . Such a1b-selectivity was detected in the present binding experiment but the functional data did not support the selectivity.
As shown in Fig. 1 , relatively good correlation was seen between binding and functional affinities of tested drugs. However, close inspection reveals somewhat consistency or inconsistency between binding and functional affinities for some drugs. Then, we categorized the tested drugs into the 5-HT1-receptor group (spiroxatrine, 5-methylurapidil, PAPP, cyanopindolol, NAN-190, BMY7378) and 5-HT2-receptor group (ketanserin, spiperone, mianserin, ritanserin, risperidone, cyproheptadine) and plotted their affinities (Fig. 2) . A good correlation can be seen only in the 5-HT1-receptor group at the three a1-adrenoceptor subtypes. In contrast, no correlation was found in the 5-HT2-receptor group at a1b-and a1d-subtypes: that is, wide variation of functional affinities being detected in spite of their relatively constant binding affinities. An approximately 500-fold difference was detected between binding and functional affinities at a 1b(a 1B)-adrenoceptor, especially for ritanserin. Such low functional affinity for ritanserin was also obtained in the concentration response curve for phenylephrine at the a1B-adrenoceptor of rat spleen (I. Muramatsu, unpublished observation). At present, we Tables 1 and 2. have no explanation for this discrepancy between binding and functional affinities. However, this evidence suggests that some drugs can show distinct potency in physiological response from the binding affinity.
The discrepancy between binding and functional affinities remind us of the a1L-adrenoceptor hypothesis (18, 19, 29) , in which contractile responses to noradrenaline in some blood vessels and lower urinary system have been considered to be mediated through prazosin-low sensitive (putative a1L-) adrenoceptors, not through prazosin-high sensitive adrenoceptors (a1A-, a1B-and a1D-subtypes). However, Ford and coworkers (30) have recently suggested that a1L-adrenoceptor may be a functional phenotype of a1A-adrenoceptor which shows high affinity for prazosin Tables 1 and 2. in the binding study but low affinity in the functional study. Since a 1b(a 1B)-adrenoceptor shows high affinity for prazosin in binding and functional studies, ritanserin may be a good probe at a1b(a1B)-adrenoceptor to explore the reasons why a given drug has different functional and binding affinities. We are now examining this point with ritanserin.
It is interesting to note that clinically active antipsychotics such as clozapine have high affinity to a1-adrenoceptors. Similar results were reported in the binding study with rat hippocampus membrane (31) . The binding and functional affinities for clozapine to a1-adrenoceptors obtained in the present study are close to its affinities to 5-HT receptor (pKi = 8.2 -8.3 for 5-HT2 receptor) (32, 33) , but higher than that at the dopamine receptor (pKi = 6.8 for D1 receptor, 7.0 for D2 receptor) (32) . Because a1-adrenoceptors widely distribute and function in the brain (1, 3) , it is likely that antagonistic effects of many antipsychotics on a1-adrenoceptor activity cannot be neglected upon consideration of their clinical effects (33, 34) .
In conclusion, the present study indicates that 5-HT receptor antagonists and agonists have relatively high affinities to a 1-adrenoceptor subtypes, suggesting that their actions on a1-adrenoceptors should be considered in the case of experimental and clinical uses. Furthermore, inconsistency between functional and binding affinities must be explored in further studies.
